Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Vernivia** is a CE-certified, over-the-counter, antibiotic-free vaginal mousse developed for the treatment of **bacterial vaginosis**, a common vaginal infection caused by an imbalance in the vaginal flora[2][3][5]. Vernivia's unique mousse formulation enables effective distribution and rapid symptom relief (often within 12 hours), with curative effect demonstrated in clinical studies. Unlike antibiotic treatments, Vernivia does **not contribute to antimicrobial resistance** and does not lead to secondary fungal infections. The product is based on Pharmiva's proprietary Venerol drug delivery platform, designed to restore normal vaginal flora and support the body's natural defenses[3]. It is marketed primarily in Sweden and Europe, with ongoing clinical and real-world studies supporting its efficacy and safety[3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vernivia.